contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


expres2ion-biotechnologies-presentation-of-q3-2024-report-recording

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Head of Equities

Michael Friis

ExpreS2ion is a biotechnology company focused on the development of vaccines. The company aims to contribute to healthcare by developing vaccines that support disease prevention and improve quality of life globally. ExpreS2ion utilizes its ExpreS2™ technology platform, which has been validated in Phase III clinical studies, for the development and production of vaccine components. Among its ongoing projects, ExpreS2ion is advancing ES2B-C001, a HER2-cVLP breast cancer vaccine undergoing Phase I clinical trials.

Biotekdirektør smager egen medicin: Deltager i klinisk forsøg med coronavaccine Adm. direktør Bent U. Frandsen fra biotekselskabet Expres2ion er blandt de 3000 frivillige, der har meldt sig til at deltage i vaccineselskabet Bavarian Nordics fase 3-forsøg med deres fælles udviklede covid-19 vaccine. Tidligere på ugen fik topchefen et vaccinestik. Jeg synes det er for cool!, men også meget tilfældigt med selve udvælgelsen. Du kan læse hele Bents egen kommentar her:                   linkedin.com              Bent Frandsen on LinkedIn: #covid19vaccine #clinicalstudy #phase3 | 16 comments    👍🏻 GETTING A TASTE OF MY OWN MEDICINE 👏🏻  This week I got a shot of COVID-19 vaccine in the ABNCoV2 Phase 3 clinical study in Denmark. How often do... 16 comments on LinkedIn

ExpreS2ion Biotechnologies offentliggjorde i morges deres tal for deres Q3 rapport, hvor de i den forbindelse afholdte en præsentation af netop denne for 2022. Jeg synes det var et spændende event, hvor de både nåede ind på deres resultater, mens de også tog et dybere kig på deres omkostninger. Dernæst nåede de ogå omkring deres Covid-19 vaccinekandidat og tog et kig på markedet som helhed. Afsluttende snakkede de desuden om nogle af de andre produktkandidater, som de har i deres pipeline

Husk at læse hele vores research disclaimer på https://www.inderes.dk/disclaimer. Dansk:  ExpreS2ion er en biotekvirksomhed med base i Danmark, men børsnoteret i Sverige. Virksomheden udvikler en portefølje af vacciner mod sygdomme som COVID-19, influenza og brystkræft gennem brugen af dets cellebaserede ekspressionssystem, ExpreS2, som er anerkendt for at håndtere protein udfordringer. ExpreS2ion har udviklet Expres2, som er en teknologiplatform til effektiv og hurtig ikke-klinisk udvikling og produktion af komplekse proteiner til nye vacciner og diagnostik. På nuværende tidspunkt er selskabets primære produkt corona-vaccinekandidaten, ABNCoV2 som er i fase 2, udviklet sammen med sin partner, AdaptVac, hvoraf ExpreS2ion ejer 34%. Vaccinekandidatens licensret tilhører Bavarian Nordic som har globale kommercialiseringsrettigheder og ansvar for yderligere klinisk udvikling af vaccinen. English:  ExpreS2ion is a Danish-based biotech company listed in Sweden. The company develops a portfolio of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral cell-based expression system, ExpreS2, which is recognized for handling protein challenges. ExpreS2ion has developed Expres2, which is a technology platform for efficient and fast non-clinical development and production of complex proteins for new vaccines and diagnostics. The company’s current primary product is the corona vaccine candidate, ABNCoV2 in phase 2, co-developed with its partner, AdaptVac of which ExpreS2ion owns 34% of. The vaccine candidate has been licensed to Bavarian Nordic has global commercialization rights and responsibility for further clinical development of the vaccine and is expected to initiate phase 3 testing for the product candidate in the first half of 2022.

ExpreS2ion Biotech Holding

Today, ExpreS2ion Biotechnologies’ CEO Bent U. Frandsen and CFO Keith Alexander presented the results and update on business for the third quarter of 2024. Furthermore, they gave some insight into the latest developments in the pipeline including the term sheet agreement on the malaria candidate and progress on the CMV candidate.

Today, ExpreS2ion Biotechnologies&#x2019; CEO Bent U. Frandsen and CFO Keith Alexander presented the results and update on business for the third quarter of 2024. Furthermore, they gave some insight into the latest developments in the pipeline including the term sheet agreement on the malaria candidate and progress on the CMV candidate.
Watch the recording here:
<a href="https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2024" target="_blank" rel="noopener">https://www.inderes.dk/videos/expres2ion-biotechnologies-presentation-of-q3-2024</a>
ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its non-viral Drosophila S2 cells-based expression system.
Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 16:02, 14-11-2024.